SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
XOMA. Bull or Bear?
An SI Board Since July 1996
Posts SubjectMarks Bans Symbol
17367 72 0 XOMA
Emcee:  Olu Emuleomo Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
17292excerpts from TSC report.. ....In conjunction with its results, management provbob zagorin-3/9/2007
17291i added a little more today...good report...bob zagorin-3/9/2007
17290Zacks Update We continue to rate shares of Xoma a buy after the fourth quarter bob zagorin-3/9/2007
17289XOMA Reports 2006 Results Thursday March 8, 4:00 pm ET Significant Revenue Growtbob zagorin-3/9/2007
17288XOMA Reports 2006 Results Thursday March 8, 4:00 pm ET Significant Revenue Growtbob zagorin-3/8/2007
1728710k xml.10kwizard.combob zagorin-3/8/2007
17286XOMA Announces Automatic Conversion of All Remaining Outstanding Convertible Notbob zagorin-3/7/2007
17285and form zacks.. XOMA Deals Keep Strengthening Posted Fri Mar 02, 01:56 pm ETbob zagorin-3/5/2007
17284a little more detail.. they have rated a one. ...Xoma (XOMA:Nasdaq, $3.10; 2,50bob zagorin-3/5/2007
17283street.com analyst bullish on xoma about 3:20 into this video.. thestreet.combob zagorin-3/2/2007
17282XOMA Announces March 8 Conference Call and Webcast Discussion of Fourth Quarter bob zagorin-3/2/2007
17281new 6% owner xml.10kwizard.combob zagorin-2/28/2007
17280XOMA Announces Expiration of Oncology Exclusivity Obligation With Novartis Wednebob zagorin-2/28/2007
17279XOMA and Takeda Expand Collaboration for Therapeutic Antibody Discovery and Devebob zagorin-2/28/2007
17278XOMA Announces Planned Retirement of Chief Executive Officer Monday February 26,bob zagorin-2/26/2007
17277and a little more from Q :...-- XOMA entered into a five-year, $35.0 million tebob zagorin-2/23/2007
17276some background.. XOMA to Receive New Royalty Stream From Bacterial Production bob zagorin-2/23/2007
17275Cimzia PIII results - Message 23310959nigel bates-2/23/2007
17274<b>It’s Alive! Meet One of Biotech’s Zombies</b> By ANDREW POLLACK Glenn Petersen-2/11/2007
17273XOMA to Present At Two Investor Conferences in February Friday February 9, 12:19bob zagorin-2/9/2007
17272xoma added to thestreet.com's stocks under $10 portfolio with a good writeupbob zagorin-2/6/2007
17271Nice gain on no news and good vol.nowandthen-2/5/2007
17270Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patientnigel bates-2/2/2007
17269a little more detail.. Novartis Drug Gets Approval In EU to Treat Eye Disease Bbob zagorin-1/25/2007
17268Lucentis approved in the EU.nigel bates-1/24/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News